JP2016501878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501878A5 JP2016501878A5 JP2015545601A JP2015545601A JP2016501878A5 JP 2016501878 A5 JP2016501878 A5 JP 2016501878A5 JP 2015545601 A JP2015545601 A JP 2015545601A JP 2015545601 A JP2015545601 A JP 2015545601A JP 2016501878 A5 JP2016501878 A5 JP 2016501878A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrinogen
- group
- solution
- vwf
- factor viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 108010049003 Fibrinogen Proteins 0.000 claims 12
- 102000008946 Fibrinogen Human genes 0.000 claims 12
- 229940012952 fibrinogen Drugs 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 108010047303 von Willebrand Factor Proteins 0.000 claims 10
- 102100036537 von Willebrand factor Human genes 0.000 claims 10
- 229960001134 von willebrand factor Drugs 0.000 claims 10
- 108010054218 Factor VIII Proteins 0.000 claims 9
- 102000001690 Factor VIII Human genes 0.000 claims 9
- 229960000301 factor viii Drugs 0.000 claims 9
- 239000012539 chromatography resin Substances 0.000 claims 8
- 239000002994 raw material Substances 0.000 claims 8
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 102000035195 Peptidases Human genes 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 102000013566 Plasminogen Human genes 0.000 claims 3
- 108010051456 Plasminogen Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 3
- 208000002004 Afibrinogenemia Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000005571 anion exchange chromatography Methods 0.000 claims 2
- 230000002779 inactivation Effects 0.000 claims 2
- 239000011347 resin Substances 0.000 claims 2
- 229920005989 resin Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 1
- DAPOMFMFTBUAKL-UHFFFAOYSA-N 2-ethylpyridine-3-thiol Chemical compound CCC1=NC=CC=C1S DAPOMFMFTBUAKL-UHFFFAOYSA-N 0.000 claims 1
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 claims 1
- 206010016075 Factor I deficiency Diseases 0.000 claims 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000003957 anion exchange resin Substances 0.000 claims 1
- 201000007182 congenital afibrinogenemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 238000011067 equilibration Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733761P | 2012-12-05 | 2012-12-05 | |
| US61/733,761 | 2012-12-05 | ||
| EP13153898 | 2013-02-04 | ||
| EP13153898.5 | 2013-02-04 | ||
| US13/803,740 | 2013-03-14 | ||
| US13/803,740 US20140154233A1 (en) | 2012-12-05 | 2013-03-14 | Method of purifying therapeutic proteins |
| AU2013203357A AU2013203357B2 (en) | 2012-12-05 | 2013-04-10 | A method of purifying therapeutic proteins |
| AU2013203357 | 2013-04-10 | ||
| PCT/AU2013/001414 WO2014085861A1 (en) | 2012-12-05 | 2013-12-05 | A method of purifying therapeutic proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178301A Division JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501878A JP2016501878A (ja) | 2016-01-21 |
| JP2016501878A5 true JP2016501878A5 (enExample) | 2017-01-19 |
| JP6411360B2 JP6411360B2 (ja) | 2018-10-24 |
Family
ID=47630209
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545601A Active JP6411360B2 (ja) | 2012-12-05 | 2013-12-05 | 治療タンパク質の精製方法 |
| JP2018178301A Active JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
| JP2021016182A Active JP7774384B2 (ja) | 2012-12-05 | 2021-02-04 | 治療タンパク質の精製方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178301A Active JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
| JP2021016182A Active JP7774384B2 (ja) | 2012-12-05 | 2021-02-04 | 治療タンパク質の精製方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20140154233A1 (enExample) |
| EP (2) | EP3483173A1 (enExample) |
| JP (3) | JP6411360B2 (enExample) |
| KR (2) | KR102403847B1 (enExample) |
| CN (2) | CN109125714B (enExample) |
| AU (2) | AU2013203357B2 (enExample) |
| BR (1) | BR112015012854B1 (enExample) |
| CA (2) | CA3185085A1 (enExample) |
| PL (1) | PL2928905T3 (enExample) |
| RU (1) | RU2685956C2 (enExample) |
| SG (2) | SG11201504372UA (enExample) |
| WO (1) | WO2014085861A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013135684A1 (en) | 2012-03-13 | 2013-09-19 | Octapharma Ag | Improved process for production of fibrinogen and fibrinogen produced thereby |
| US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
| US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
| GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| GB201506117D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| WO2017118910A1 (en) * | 2016-01-07 | 2017-07-13 | Eio Biomedical Ltd | Methods, compositions and kits for reducing tissue adhesions |
| WO2018007767A1 (fr) | 2016-07-06 | 2018-01-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Fibrinogène liquide stable |
| IL265102B2 (en) * | 2016-09-01 | 2023-11-01 | Plas Free Ltd | Human Blood-Derived Products Having Decreased Fibrinolytic Activity And Uses Thereof In Hemostatic Disorders |
| KR20200038309A (ko) * | 2017-08-23 | 2020-04-10 | 체에스엘 베링 게엠베하 | 폰 빌레브란트 인자의 바이러스 여과 방법 |
| CN109078628B (zh) * | 2018-08-27 | 2021-06-11 | 西北大学 | 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用 |
| FR3090321B1 (fr) * | 2018-12-21 | 2023-07-14 | Lab Francais Du Fractionnement | Procédé de filtration du fibrinogène |
| US20220380439A1 (en) | 2020-11-09 | 2022-12-01 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
| CA3215331A1 (en) | 2021-04-13 | 2022-10-20 | Toshiharu Motokubota | Liquid composition comprising factor viii or factor viii/von willebrand factor complex |
| CN115181178B (zh) * | 2021-09-04 | 2024-04-26 | 广东双林生物制药有限公司 | 一种从冷沉淀中制备人纤维蛋白原的方法 |
| MX2024008243A (es) | 2021-12-30 | 2024-09-04 | Baxter Int | Soluciones de fibrinogeno y trombina para un sellador de fibrina y un kit de sellador de fibrina. |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| FR2632309B1 (fr) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
| CA2117058A1 (en) * | 1991-09-05 | 1993-03-18 | Daphne C. Tse | Topical fibrinogen complex |
| FR2686883B1 (fr) * | 1992-02-04 | 1994-05-13 | Aquitaine Develop Transf Sanguin | Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant. |
| CA2195127C (en) * | 1994-07-14 | 2007-06-19 | Ruth Laub | Concentrate of fibrinogene obtained from blood plasma, process and plant for its preparation |
| AU3463495A (en) * | 1994-09-02 | 1996-03-27 | New York Blood Center, Inc., The | Production and secretion of recombinant fibrinogen by yeast |
| US6037457A (en) * | 1997-01-31 | 2000-03-14 | The University Of North Carolina At Chapel Hill | Method for recombinant fibrinogen production |
| FR2772381B1 (fr) | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
| DE69931645T2 (de) * | 1998-09-24 | 2007-05-16 | Pharming Intellectual Property Bv | Reinigung von fibrinogen aus flüssigkeiten mittels ausfällung und hydrophobischer-interaktion-chromatographie |
| DE60042343D1 (de) * | 1999-12-23 | 2009-07-16 | Csl Ltd | Abtrennung von fibrinogen von plasmaproteasen |
| WO2001046016A1 (en) | 1999-12-23 | 2001-06-28 | Rast Rodger H | System and method for providing individualized dosing |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| PL205685B1 (pl) * | 2001-05-21 | 2010-05-31 | Omrix Biopharm Sa | Sposób in vitro usuwania lub wyodrębniania plazminogenu lub plazminy w obecności fibrynogenu, stałe podłoże powinowactwa do oczyszczania mieszaniny zawierającej fibrynogen i plazminę i/lub plazminogen oraz krioprecypitat |
| AUPR638801A0 (en) | 2001-07-13 | 2001-08-09 | Life Therapeutics Limited | Factor viii separation |
| JP2005508925A (ja) * | 2001-10-03 | 2005-04-07 | クリストファー ジェイ ウールヴァートン | 貯蔵安定なフィブリノーゲン溶液 |
| AU2002340776A1 (en) * | 2001-10-30 | 2003-05-12 | Novozymes A/S | High throughput isolation of proteins by charge induction chromatography |
| DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
| JP4319979B2 (ja) * | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | タンパク質の非アフィニティ精製 |
| GB0216001D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| DE10261126A1 (de) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
| DE10246125A1 (de) | 2002-10-01 | 2004-04-15 | Aventis Behring Gmbh | Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren |
| ES2214967B1 (es) | 2003-03-06 | 2005-06-16 | Probitas Pharma, S.A | Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento. |
| DE102004009400A1 (de) * | 2004-02-24 | 2005-09-08 | Zlb Behring Gmbh | Fibrinogen Reinigung |
| CA2583081A1 (en) * | 2004-06-16 | 2006-01-19 | Bio-Rad Laboratories, Inc. | Multichemistry fractionation |
| ATE546520T1 (de) * | 2007-01-04 | 2012-03-15 | Crucell Holland Bv | Faktor-xi-reinigung |
| EP2167526B1 (en) | 2007-07-11 | 2011-03-30 | Novo Nordisk A/S | Purification of factor viii using a mixed-mode or multimodal resin |
| EP2027875A1 (en) * | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
| FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
| WO2009090056A2 (en) | 2008-01-18 | 2009-07-23 | F. Hoffmann-La Roche Ag | Purification of not-glycosylated polypeptides |
| SI2300497T1 (sl) * | 2008-06-24 | 2013-02-28 | Octapharma Ag | Postopek za äťiĺˇäťenje koagulacijskega faktorja viii |
| CA2785594C (en) * | 2010-01-08 | 2018-04-17 | Profibrix Bv | Fibrinogen preparations enriched in fibrinogen with an extended alpha chain |
| ES2586698T3 (es) * | 2010-09-20 | 2016-10-18 | Octapharma Ag | Proceso para la producción de fibrinógeno |
| EP2649087A1 (en) * | 2010-12-08 | 2013-10-16 | Amgen Inc. | Ion exchange chromatography in the presence of an amino acid |
| WO2013135684A1 (en) | 2012-03-13 | 2013-09-19 | Octapharma Ag | Improved process for production of fibrinogen and fibrinogen produced thereby |
| US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
-
2013
- 2013-03-14 US US13/803,740 patent/US20140154233A1/en not_active Abandoned
- 2013-04-10 AU AU2013203357A patent/AU2013203357B2/en active Active
- 2013-12-05 SG SG11201504372UA patent/SG11201504372UA/en unknown
- 2013-12-05 RU RU2015126551A patent/RU2685956C2/ru active
- 2013-12-05 CN CN201811091750.9A patent/CN109125714B/zh active Active
- 2013-12-05 EP EP18207150.6A patent/EP3483173A1/en active Pending
- 2013-12-05 WO PCT/AU2013/001414 patent/WO2014085861A1/en not_active Ceased
- 2013-12-05 EP EP13861334.4A patent/EP2928905B1/en active Active
- 2013-12-05 KR KR1020217010484A patent/KR102403847B1/ko active Active
- 2013-12-05 CA CA3185085A patent/CA3185085A1/en active Pending
- 2013-12-05 SG SG10201704484QA patent/SG10201704484QA/en unknown
- 2013-12-05 PL PL13861334T patent/PL2928905T3/pl unknown
- 2013-12-05 JP JP2015545601A patent/JP6411360B2/ja active Active
- 2013-12-05 CN CN201380063945.1A patent/CN104981476B/zh active Active
- 2013-12-05 BR BR112015012854-8A patent/BR112015012854B1/pt active IP Right Grant
- 2013-12-05 KR KR1020157017824A patent/KR102240978B1/ko active Active
- 2013-12-05 AU AU2013354899A patent/AU2013354899B2/en active Active
- 2013-12-05 CA CA2893373A patent/CA2893373A1/en not_active Abandoned
-
2014
- 2014-11-06 US US14/535,085 patent/US9598461B2/en active Active
-
2017
- 2017-02-03 US US15/424,072 patent/US20170143805A1/en not_active Abandoned
-
2018
- 2018-09-25 JP JP2018178301A patent/JP6836562B2/ja active Active
- 2018-12-10 US US16/214,519 patent/US11426680B2/en active Active
-
2021
- 2021-02-04 JP JP2021016182A patent/JP7774384B2/ja active Active
- 2021-03-01 US US17/188,173 patent/US20210283530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501878A5 (enExample) | ||
| Franchini et al. | The history of hemophilia | |
| RU2015126551A (ru) | Способ очистки лечебных белков | |
| Walsh et al. | The burden of inhibitors in haemophilia patients | |
| Teoh et al. | p53 abnormalities and potential therapeutic targeting in multiple myeloma | |
| AR091967A1 (es) | Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept | |
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2018521135A5 (enExample) | ||
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| RU2014143639A (ru) | Регулируемые протеазой антитела | |
| ES2829923T3 (es) | Un proceso novedoso de purificación para el aislamiento y la producción comercial de tnk-tpa recombinante (tenecteplase) | |
| CN102584983B (zh) | 一种分离纯化凝血因子viii的方法 | |
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| Ettingshausen et al. | The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? | |
| JP2015514115A5 (enExample) | ||
| RU2015121574A (ru) | Препарат для биспецифических активаторов т-клеток(bite) | |
| JP2014525417A5 (enExample) | ||
| K. Lau et al. | Thrombotic complications of neonates and children with congenital nephrotic syndrome | |
| Di Minno et al. | Management of patients with long‐term inhibitors: is immune tolerance an underestimated life‐long solution? | |
| JP2016501875A5 (enExample) | ||
| RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Goubran et al. | New monoclonal/bi-specific antibodies: reshaping transfusion medicine beyond replacement | |
| JP2008517046A5 (enExample) | ||
| Ofosu et al. | The fraction of recombinant factor VIII: Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro |